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Abstract Blepharospasm is a focal dystonia in which the
extraocular muscles contract repetitively, leading to
excessive blinking and forced eyelid closure. Botulinum
toxin type A (BoNTA) is the primary symptomatic treat-
ment for blepharospasm and its effects have been evaluated
using numerous rating scales. The main scales in use today
were initially used to determine whether BoNTA treatment
was superior to placebo, and most controlled trials have
conﬁrmed this. More recently, these scales have been used
to determine whether there are efﬁcacy differences
between different BoNTs in blepharospasm. However,
although the scales used in these trials are able to differ-
entiate the effects of BoNT from placebo, they may not be
sensitive enough to differentiate between BoNTs. Most of
the scales include only four possible points for each item,
which would necessitate a 25% greater improvement in one
group than the other to detect any differences. Current
scales are also relatively insensitive to patients with mild
disability who may experience mainly psychosocial prob-
lems related to their blepharospasm. Clinical trials com-
paring BoNTs that include substantial numbers of mildly
affected patients may be unlikely to ﬁnd differences
because the scales do not adequately measure mild symp-
toms. Additional challenges with evaluating blepharo-
spasm include the lack of precision and objectivity of
current measures, symptom variability, the need to evaluate
aspects of the disorder that are most important to patients,
and the different types of blepharospasm. Although no
single scale may be able to capture all relevant aspects of
blepharospasm, more sensitive and patient-centered scales
are needed.
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Introduction
Blepharospasm, literally ‘‘spasm of the eyelid’’, is a focal
dystonia characterized by involuntary eyelid closure
(Hallett 2002). Although blepharospasm like symptoms
can occur secondarily to certain neurologic or ophthalmic
disorders or lesions, the etiology is often unknown; in that
case it is referred to as idiopathic, essential, or primary
blepharospasm (Hallett 2002). Blepharospasm can range in
severity from mild cases that do not appreciably interfere
with daily activities to severe cases that render individuals
functionally blind, preventing them from driving, working,
reading, and walking.
Botulinum neurotoxin (BoNT) injections are a primary
symptomatic treatment for blepharospasm. BoNTs act by
inhibiting the release of acetylcholine at the neuromuscular
junction, which reduces excessive muscular contractions
and helps normalize muscle activity. The effects of BoNTs
are reversible and temporary, lasting approximately
3 months in the treatment of blepharospasm (Jankovic and
Orman 1987; Nussgens and Roggenkamper 1995).
A number of different measurement tools and scales
have been used to evaluate the effects of BoNT on various
aspects of blepharospasm, including force of eyelid clo-
sure, severity of muscle spasms, and patient functional
status (Cohen et al. 1986; Elston and Russell 1985; Scott
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into several main clinical scales, including the Jankovic
Rating Scale (JRS) and Blepharospasm Disability Index
(BSDI). Historically, duration of the beneﬁcial effect has
been used as a stand-alone measure of BoNT efﬁcacy
(Nussgens and Roggenka ¨mper 1997), but today is typically
considered complementary to existing efﬁcacy scales.
In any disorder, precise and meaningful measures of
improvement or deterioration in signs and/or symptoms are
important in order to evaluate the patient’s disease state
and the effects of the therapy. This review examines the
different methods of blepharospasm assessment, beginning
with a historical overview of early measures and pro-
ceeding to a discussion of current scales and their use in
BoNT clinical studies. The paper concludes with a dis-
cussion and suggestions of how best to assess the efﬁcacy
of blepharospasm therapy.
Historical overview of blepharospasm measurement
Force of eyelid closure
Early studies of BoNT injections examined force of eyelid
closure in grams using an external device that prevents
downward movement of the upper eyelid [e.g., (Scott et al.
1985)].However,forceofeyelidclosureisnotwidelyusedas
an outcome measure today, as treatments for blepharospasm
would ideally resolve muscle spasms while leaving eyelid
force normal. With the use of BoNT, paralysis of the orbicu-
larismuscleisnotnecessaryforoptimalbeneﬁt.Inthissense,
we do not agree with the scale developed by Rahman et al.
(2003) in which orbicularis function is assessed as the ability
of observers to manually open the eyelids of patients who are
attempting to close their eyelids forcefully.
Muscle spasm
Several different muscle spasm scales were reported in the
1980s. Tsoy et al. (1985) used a scale that ranged from
0 = absent to 4 = extreme to rate the intensity of orbicularis
oculi muscle spasm, as well as brow spasm. A scale used by
Cohen et al. (1986) combined spasm intensity and functional
ratings that ranged from 0 = none, 1 = increased blinking
causedbyexternalstimuli,2 = mildﬂutteringofthe lids,not
incapacitating,3 = moderatespasmwithmildincapacitation,
and 4 = severe spasm resulting in incapacitation (unable to
drive, read, etc.).
Fahn scale
The Fahn rating scale for blepharospasm, developed in the
1980s, consists of a movement subscale and a disability
scale (Fahn 1985). The movement subscale incorporates
the location of involuntary movements (one point for each
muscle area), as well as one point for each external factor
that inﬂuences the dystonia (sunlight, television, etc.)
(Fahn 1985). The frequency of involuntary movements is
rated according to the percentage of waking time that
movements are present (ﬁve different frequency catego-
ries), and severity of eyelid closure is rated from
0 = absent to 4 = severe, forceful eyelid contractions. The
disability subscale consists of seven everyday activities
(driving, reading, television, movies, shopping, walking,
housework/job) for which the degree of impairment is rated
according to descriptors that increase in severity from 1 to
3 or 1 to 5 (Fahn 1985). An eighth item documents the need
to wear sunglasses outdoors (1 point) and indoors (1 point).
Elston functional status scales
In the 1980s and early 1990s, Elston and Russell (1985)
developed a series of scales that focused on the functional
status of blepharospasm patients following BoNT injections.
The ﬁrst of these scales ranged from 1 = functionally blind
(eyesshutfor[80%ofday)to3= inconvenienced(eyesshut
for 10–30% of day). In a subsequent study, Elston and col-
leagues asked patients to evaluate the percentage of the day
spent functionally blind before and after BoNT injections
(Grandasetal. 1988).A thirdscale bythisgrouprangedfrom
1 = blind, 2 = dependent outside home, 3 = independent,
poor function, 4 = independent, moderate function, 5 =
inconvenienced, 6 = normal (Elston 1992).
Current blepharospasm scales and their use in BoNT
trials
Current blepharospasm rating scales are largely modiﬁed
versions of previous scales that have been altered for ease
of use or to remedy one or more inadequacies of previous
scales. Current scales fall into three general categories:
(i) clinical scales, (ii) activities of daily living/functional
ability status scales, and (iii) global rating scales. Each of
these scale types has been used in recent studies comparing
the effects of different BoNTs in blepharospasm. In this
section, we brieﬂy review the three general types of scales
and, for each type, consider the beneﬁts and drawbacks
based on its use in recent BoNT trials.
Overview of clinical scales
Clinical scales focus on clinical signs and/or symptoms and
are rated by observers as opposed to patients. These scales
often take the form of ordinal, numeric ratings anchored by
descriptors. Blepharospasm clinical rating scales in use
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scales developed by Fahn (1985).
The Jankovic Rating Scale (JRS) is probably the most
widely used current clinical scale (Fig. 1) (Jankovic and
Orman 1987). The two subscales that make up the JRS—
severity and frequency—are 5-point scales ranging from
0 to 4, where 0 indicates no symptoms and 4 indicates the
most severe or frequent symptoms. As can be seen from
the descriptions in Fig. 1, the JRS primarily focuses on the
objective signs of blepharospasm but does incorporate
some subjective symptoms such as whether the increased
blinking and spasms are incapacitating, as judged by the
observer.
Advantages of the JRS include its relative simplicity and
broad applicability for both patients and physicians. The
evaluations required for the scale are readily performed in
an ofﬁce setting without the need for complex equipment
or scoring procedures. Disadvantages of the JRS may
include a lack of sensitivity to small changes in blepharo-
spasm severity or frequency, particularly at the mild end of
the spectrum where patients must change from increased
blinking in response to external stimuli (a score of ‘‘1’’) to
‘‘none’’ in order for an improvement in their condition to
be documented on the severity scale. Additionally, the
scale does not take into account how the patient’s bleph-
arospasm affects his or her daily activities. It may be noted
that a JRS sum score of 1 is not possible, as even mild
symptoms (severity score = 1) occurring at the lowest
frequency (frequency = 1) give a sum score of 2.
Table 1 lists published clinical studies that were ran-
domized or enrolled at least 50 patients and were designed
to evaluate the effects of BoNTs for blepharospasm; as can
be seen in this table, a number of these studies used the
JRS. It should be noted that various studies have used
different versions of the same scale. For example, (Mezaki
et al. 1999) used a scale modiﬁed from the JRS blepharo-
spasm frequency scale.
Jankovic Rating Scale in 2006 BoNTA non-inferiority
trial (Roggenka ¨mper et al. 2006)
The JRS was used as the primary outcome measure in a
randomized, controlled, non-inferiority trial comparing
Xeomin
 (Merz) to BOTOX
 (Allergan) published in
2006 (Roggenka ¨mper et al. 2006). This 16-week study
included 300 subjects with blepharospasm (n = 148/152
per group) who had achieved a stable response to two
previous injections of BOTOX
. Subjects received a single
treatment with one or the other medication based on the
doses and injection sites of their previous BoNTA treat-
ments (mean doses per eye: 19.8 units Xeomin
; 20.4 units
BOTOX
).
In this study, both BoNTA products signiﬁcantly
reduced total JRS scores versus baseline at 3 weeks and
*3.6 months. Mean baseline scores in the two groups
were comparable (5.3 Xeomin
, 5.4 BOTOX
), as were
adjusted mean improvements at 3 weeks (-2.83 Xeomin
,
-2.65 BOTOX
) and *3.6 months (-0.84 Xeomin
,
-0.66 BOTOX
). In this study, the JRS was sensitive
enough to detect post-baseline improvements with both
BoNT products; this ﬁts with the initial use of the scale,
which was to evaluate the effects of BoNTA versus pla-
cebo (Jankovic and Orman 1987).
However, the JRS may not be sensitive enough to detect
differences between two BoNT products—both of which
appear to be effective for the treatment of blepharospasm—
and indeed, it was not designed to do so. In the non-infe-
riority study, a clinically irrelevant difference in the JRS
sum score was deﬁned as 0.8 points (Roggenka ¨mper et al.
2006). Because the JRS is rated in whole numbers, a
substantial portion of subjects would have needed to rate
one or the other BoNTA as approximately 25% lower on
either the severity or frequency subscale to achieve a mean
difference of at least 0.8 (e.g., a 1-point change on a 5-point
subscale scale is approximately a 25% improvement, rec-
ognizing that the psychological distance may not be
equivalent between ordinal numbers on the scale). This
may be somewhat unlikely with two products that are both
effective for the treatment of blepharospasm.
Given these considerations with the use of the JRS (and,
as discussed later, other current scales) in studies that
compare different BoNTs, there is likely a bias toward
ﬁnding no meaningful differences between groups. Addi-
tionally, as previously noted, it may also be more difﬁcult
to detect improvements on the JRS in mild cases of
blepharospasm for which increased blinking would need to
Blepharospasm Severity 
0 = None 
1 = Minimal, increased blinking present only with external stimuli (e.g., 
bright light, wind, reading, driving, etc.) 
2 = Mild, but spontaneous eyelid fluttering (without actual spasm), 
definitely noticeable, possibly embarrassing, but not functionally 
disabling) 
3 = Moderate, very noticeable spasm of eyelids only, mildly 
incapacitating 
4 = Severe, incapacitating spasm of eyelids and possibly other facial 
muscles 
Blepharospasm Frequency 
0 = None 
1 = Slightly increased frequency of blinking 
2 = Eyelid fluttering lasting less than 1 second in duration 
3 = Eyelid spasm lasting more than 1 second, but eyes open more 
than 50% of the waking time 
4 = Functionally “blind” due to persistent eye closure (blepharospasm) 
more than 50% of the waking time 
Fig. 1 Jankovic Rating Scale (Jankovic and Orman 1987)
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Finally, as a clinical scale evaluating two dimensions of
blepharospasm (severity and frequency), nuances in the
effects of two different BoNTAs, for instance, in quality of
life measures or other more subjective criteria would not be
detected.
Table 1 Studies of BoNT treatment of essential blepharospasm (limited to controlled studies of any size and open-label studies with C50
patients)
a
References Study design BoNT Number of
blepharospasm
patients
Efﬁcacy outcome
measure(s)
Results/remarks
(Fahn et al. 1985) Within subjects,
placebo controlled
Botox 8 Electrophysiology BoNTA signiﬁcantly reduced evoked
potentials, contractions at rest, and
maximally forced contractions versus
placebo
(Frueh et al. 1988) Randomized, double-
blind, placebo-
controlled
Botox 26 Patient subjective
improvement (no scale
mentioned)
Similar effects in lower eyelid with
BoNTA and placebo
(Grandas et al. 1988) Retrospective Dysport 151 % Improvement (in 25%
increments)
62% reported at least 50%
improvement, with 36% indicating
restoration of relatively normal
vision
(Girlanda et al. 1996) Prospective, placebo
controlled
Botox 6 Electrophysiology, JRS
severity scale
Similar improvements on both
measures with placebo and BoNTA
(Mauriello et al. 1996) Retrospective Botox 222 Duration (deﬁnition not
speciﬁed)
Mean duration 14.9 weeks
(Nussgens and
Roggenka ¨mper 1997)
Randomized, double-
blind, crossover
Botox versus Dysport 212 Duration (deﬁnition not
speciﬁed)
Mean duration 8 weeks both BoNTAs
(no signiﬁcant difference)
(Price et al. 1997) Randomized, different
injection sites
Not speciﬁed 50 Duration (deﬁnition not
speciﬁed)
Standard injection sites led to longer
duration than brow or inner/outer
orbital injection sites
(Sampaio et al. 1997) Randomized,
comparison
Botox versus Dsyport 42 Duration (interval from
treatment to patient-
reportedweaningofeffect)
No signiﬁcant differences in duration
(blepharospasm results not separated
from cervical dystonia results)
(Mezaki et al. 1999) Randomized,
comparison
Chiba A versus F
versus A ? F
54 JRS frequency scale,
Patient-rated severity
(0–100)
Peak effects similar in all groups, but
duration longest with BoNTA alone
(Roggenka ¨mper et al.
2006)
Randomized, double-
blind comparison
Botox versus Xeomin 300 JRS, BSDI, Patient Global,
Investigator Global
Both BoNTAs improved scores on all
measures; no signiﬁcant differences
between BoNTAs
(Rieder et al. 2007) Randomized, double-
blind comparison
Botox versus Prosigne 8 Subjective global
improvement, duration
Both BoNTAs led to subjective global
improvement; no signiﬁcant
differences between BoNTAs
(Truong et al. 2008) Randomized, double-
blind, placebo-
controlled multi-dose
Dysport 120 BDS, SRS, FIM, Global
impairment (VAS)
Signiﬁcant improvement with BoNTA
on all measures
(Boyle et al. 2009) Randomized, different
dilutions
Botox 16 Pain, bruising, redness
rated on 1–10 scale,
duration of symptom
relief
58% greater reduction in pain with
high concentration than low
concentration; no difference on other
measures
(Quagliato et al. 2010) Randomized, double-
blind comparison
Botox versus Prosigne 21 SF-36, duration Both BoNTAs improved scores on SF-
36 emotional aspects domain, no
signiﬁcant differences between
BoNTAs
(Yoon et al. 2009) Randomized, double-
blind comparison
Botox versus
Meditoxin
60 Rating scales for severity of
spasm, eyelid closing
force, functional visual
status
Both BoNTAs improved scores on all
measures; no signiﬁcant differences
between BoNTAs
(Wabbels et al. 2010) Randomized, double-
blind, comparison
Botox versus Xeomin 65 BSDI, JRS, Patient global
assessment
Both BoNTAs improved scores on all
measures; no signiﬁcant differences
between BoNTAs in main analyses
BoNTA botulinum toxin type A, BSDI Blepharospasm Disability Index, FIM functional independence measure, JRS Jankovic Rating Scale, SRS Severity Rating
Scale, VAS visual analog scale
a Based on a search of PubMed database; key words: botulinum and blepharospasm, limited to English or German language. Articles identiﬁed in the search were
limited to those that were either randomized, controlled trials or open-label trials with at least 50 subjects. Additional articles identiﬁed are available in the Appendix
to this paper
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status scales
In contrast to clinical scales, instruments that assess
activities of daily living or patient functional status are
rated by the patients themselves. These scales recognize
the importance of improvement in everyday activities as an
outcome of therapy (Lindeboom et al. 1995). Here we
consider functional ability scales speciﬁc to blepharospasm
as opposed to general scales such the Medical Outcomes
Study 36-item Short Form (SF-36), which assesses multiple
health-related domains (physical, social, role limitations,
bodily pain, mental health, vitality, general health) that are
not speciﬁc to blepharospasm and may or may not be
expected to improve with blepharospasm treatment.
In the 1980s and 1990s, the Blepharospasm Disability
Scale (BDS) emerged as a useful functional ability rating
scale. The BDS is an eight-item subsection of the Bleph-
arospasm Rating Scale developed by Fahn (1985). Despite
the documented reliability and validity of this scale
(Lindeboom et al. 1995), it has certain drawbacks,
including the lack of a ‘‘non-applicable’’ option for any of
the individual items.
This led to the development of the Blepharospasm
Disability Index (BSDI), which has been used in several
recent BoNT studies (Table 1). The BSDI consists of six
daily activities, each rated on a scale from 0 = no
impairment to 4 = not possible due to disease, and also
includes a ‘‘not applicable’’ option (Fig. 2) (Goertelmeyer
et al. 2002). Advantages of the BSDI include its focus on
daily activities and ease of use. The scoring system is also
relatively simple: mean item scores on the BSDI are cal-
culated by dividing the sum score by the number of
applicable items.
The Craniocervical Dystonia Questionnaire (CDQ) is a
dystonia-speciﬁc quality of life instrument consisting of
24 questions that make up six subscales: stigma, emotional
wellbeing,pain,activities ofdaily living, and social/family life
(Mu ¨ller et al. 2004). Each question is answered as ‘‘never,
occasionally, sometimes, often, or always.’’ An advantage of
this scale is that it includes questions on social and emotional
aspectsofdystoniaasopposedtofocusingsolelyonlimitations
toactivities.However,thesensitivityofthisscaleincomparing
treatments may be limited by the ﬁve-choice options.
BDS in 2008 Dysport
 (Ipsen) trial
A modiﬁed version of the BDS was used as the primary
outcome measure in a randomized, controlled study of
Dysport
 versus placebo for the treatment of blepharo-
spasm (Truong et al. 2008). This 16-week study included
120 subjects with blepharospasm who had a minimum
score of 8 out of 26 possible points on the BDS. Subjects
were assigned to receive a single treatment with placebo or
one of three Dysport
 doses: 40, 80, or 120 units/eye.
In this study, the BDS was modiﬁed to exclude ques-
tions that were not relevant for individual patients and
include an additional rating of 0 (zero) if an item was not
affected by blepharospasm. BDS scores were calculated as
the percentage of normal activity, deﬁned as ‘‘total points
scored divided by the maximum possible individual score,
multiplied by 90 and subtracted from 90% (i.e., ﬁnal
score = 90% - 90 [score/maximum possible])’’ (Truong
et al. 2008) based on the scoring system speciﬁed by Fahn
(1985). BDS outcomes were presented as differences in
median percentage of normal activity between the BoNTA
and placebo-treated groups.
Neither mean nor median baseline BDS scores were
presented in the article, but all subjects must have had a
minimum score of 8 to be included in the study. All of the
BoNTA doses tested signiﬁcantly increased the percentage
of normal activity on the BDS over placebo at weeks 4, 8,
and 12, with the two highest doses also showing signiﬁcant
improvements over placebo at week 16. Thus, as modiﬁed
in this study, the BDS was able to detect differences
between BoNTA versus placebo.
BSDI in 2006 BoNTA non-inferiority comparison trial
Although the JRS was the primary outcome measure in the
randomized, non-inferiority trial described in a previous
section, this study also included the BSDI as a secondary
outcome measure (Roggenka ¨mper et al. 2006). Mean item
scores on the BSDI were calculated at 21 and 109–112
days post-treatment. As mentioned above, mean item
scores on the BSDI are calculated by dividing the sum
score by the number of applicable items.
Items 
Reading 
Driving a vehicle 
Watching television 
Shopping 
Doing everyday activities 
Getting about on foot (walking) 
Ratings 
0 = no impairment 
1 = mild impairment 
2 = moderate impairment 
3 = severe impairment 
4 = not possible due to disease 
Not applicable 
Fig. 2 Blepharospasm Disability Index (Roggenka ¨mper et al. 2006);
scale originally described in Goertelmeyer et al. 2002
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reduced mean item scores on the BSDI versus baseline at
the two follow-up time points. Mean item scores on the
BSDI at baseline were compared in the two groups (1.67
BOTOX
, 1.60 Xeomin
), and mean improvements at
21 days (-0.83 BOTOX
, -0.82 Xeomin
) and
109–112 days (-0.22 BOTOX
, -0.36 Xeomin
) were
not signiﬁcantly different at the P\0.05 level.
BSDI in 2010 BoNTA preliminary comparison trial
Total BSDI scores were used as the primary outcome
measure in a randomized, controlled trial comparing
Xeomin
 to BOTOX
 (Wabbels et al. 2010). Total BSDI
scores are calculated as the sum of scores on all of the
BSDI items. This 14-week study included 65 subjects with
blepharospasm (n = 32/33 per group) who had received at
least one treatment with BOTOX
 C20 units/eye and
required another treatment with the same dose. Subjects
were randomized to receive a single treatment with one or
the other medication based on the doses and injection sites
of their previous BoNTA treatment (mean doses 29 units
BOTOX
, 27 units Xeomin
).
In this study, both BoNTA products signiﬁcantly
reduced total BSDI scores versus baseline at 4 and
8 weeks. Mean total baseline scores in the two groups were
compared (7.9 BOTOX
, 8.3 Xeomin
), and mean
improvements in total BSDI scores at 4 weeks (-2.8
BOTOX
, -1.3 Xeomin
) and 8 weeks (-1.3 BOTOX
,
-0.8 Xeomin
) were not signiﬁcantly different at the
P\0.05 level. Mean item scores on the BSDI were also
compared at baseline (1.39 BOTOX
, 1.44 Xeomin
), and
improvements in mean item scores on the BSDI at 4 weeks
(-0.42 BOTOX
, -0.21 Xeomin
) were not signiﬁcantly
different at the P\0.05 level.
Again, it seems possible that this scale may not be
sensitive enough to detect differences between two BoNT
products. The BSDI shares the same sensitivity issues as
the JRS in that the ratings for each category range from
0 = no impairment to 4 = not possible due to disease. As
with the JRS, the BSDI ratings consist of whole numbers,
and subjects would need to rate one or the other BoNTA as
approximately 25% lower on one of the items in order to
detect any difference between them. Again, this assumes
that a 1-point improvement on a 5-point scale constitutes
an approximately 25% improvement, recognizing that the
psychological distance may not be equivalent between
ordinal numbers on the scale. Like the JRS, the BSDI is a
modiﬁed version of a scale that was originally developed to
determine whether BoNT was more effective than pla-
cebo in the treatment of focal dystonia (Lindeboom et al.
1995).
Application of the ‘‘clinically meaningful’’
improvement criteria
Jankovic et al. (2009) recently analyzed the metric prop-
erties of the JRS and BSDI in blepharospasm patients by
evaluating the relationship between various clinical out-
come measures. These authors concluded that a 0.7-point
improvement in BSDI mean item score and a 2-point
improvement in the JRS sum score constituted clinically
relevant improvements (Jankovic et al. 2009).
It is important to point out that these criteria are only
relevant for patients whose baseline scores are [2 on the
JRS and[0.7 on the BSDI (calculated as the mean of all
BSDI item scores that are relevant for a given patient). A
case in point is the BoNTA comparison study described in
the preceding section (Wabbels et al. 2010). In this study,
only 19 of the 31 subjects (61%) in the BOTOX
 group
and 24 of 33 subjects (73%) in the Xeomin
 group had
high enough baseline BSDI scores to be included in a
responder analysis based on the Jankovic criterion (Wab-
bels et al. 2010).
Caution must therefore be used when applying the
Jankovic criteria to overall study population means; only
those whose baseline scores exceed the improvement cri-
teria can legitimately be subject to them.
Global rating scales
Global rating scales are usually general rather than disease
speciﬁc, designed to capture the overall subjective effects
of treatment. These scales can be physician or patient rated,
and are usually used as secondary instead of primary out-
come measures.
One global rating scale that has often been used in BoNT
trials is a modiﬁcation of the one developed by Brin et al.
(1995). On this scale, improvement or worsening from
baseline is rated from -4 (marked worsening in symptoms
and function) to 0 (no effect) to ?4 (marked improvement
in symptoms and function). This scale has been used in a
number of BoNTA trials in several different medical
conditions (Naumann and Lowe 2001; Roggenka ¨mper
et al. 2006; Simpson et al. 1996).
A percentage of normal function scale developed by
Brin et al. (1994; 1995) has been used in other BoNT
studies (Wissel et al. 2000). On this scale, patients are
asked to rate the function of the body part treated from 0%
(fully disabled with no functional activity) to 100% (nor-
mal function).
An advantage of patient-rated global scales is that they
permit assessment and quantiﬁcation of improvements in
symptoms or functions that are important to patients.
Because these scales are non-speciﬁc, they may consider
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ically represent a global judgment of how well the treat-
ment works. Additionally, global assessment scales that are
anchored by only a few rating descriptions such as mild,
moderate, and marked essentially have built-in clinical
relevance in that improvement from marked to moderate or
moderate to mild appears to be clinically meaningful.
However, the inclusion of such few ratings renders the
scale less sensitive than larger scales. Another drawback to
global scales is their subjectivity, with ratings possibly
inﬂuenced by psychological variables such as mental state/
mood and expectations. Patients are also typically asked to
compare their condition to baseline, which may be difﬁcult
to remember.
Global assessments in BoNT comparison trials
A 9-point global assessment scale (-4t o0t o?4)
described in the preceding section was used in both the
non-inferiority (Roggenka ¨mper et al. 2006) and pre-
liminary comparison (Wabbels et al. 2010) trials evaluating
the effects of BOTOX
 versus those of Xeomin
. In both
studies, mean improvements with the BoNTA products
were generally between ?2 and ?3, supporting a global
effect on blepharospasm. However, statistically signiﬁcant
differences between BoNTA on this measure were not
detected in either trial. As with the previously described
JRS and BSDI measures, it may not be possible to detect
subtle differences between two BoNTAs due to the
insensitivity of the scales (only four possible ratings for
improvement).
Considerations/conclusions
There are several important considerations with blepharo-
spasm scales beyond the need for reliable and valid mea-
surement of the condition. First, it must be recognized that
blepharospasm can be challenging to assess because
symptoms may vary depending on time of day, patient
stress level, lack of sleep, situation (e.g., home vs. exam-
iner’s ofﬁce), and environmental stimuli. Thus, blepharo-
spasm measurement is hindered by the variable nature of
the complaints. To address this, patients should be evalu-
ated in the same location and the same time of day, rec-
ognizing that it will not be possible to control all of the
non-medication related factors that may inﬂuence blepha-
rospasm severity during rating.
A second consideration is the lack of precision and
objectivity of current measures. For conditions such as high
blood pressure and diabetes, precise and sensitive mea-
surements can be performed using manual or electronic
devices. Historically, blepharospasm has been evaluated
using an instrument to measure eyelid force; however, as
noted previously, this is not an optimal measure for the
effects of BoNTs because the therapeutic goal is elimina-
tion of spasms while maintaining normal force of eyelid
closure. The development of alternate devices for the
measurement of blepharospasm could alleviate the sub-
jectivity issue. Of note, several studies have evaluated the
use of video nystagmography as a measurement tool for
blinking in blepharospasm before and after botulinum toxin
treatment (Casse et al. 2008, 2009). The objectivity of this
method is advantageous, although further studies are nee-
ded to assess its validity.
A third consideration is the lack of sensitivity of current
rating scales. Clearly, more sensitive scales are needed if
we are to accurately compare the effects of different
BoNTs in the treatment of blepharospasm. Current scales,
which were initially used to determine whether BoNTs
were superior to placebo, are probably biased against
ﬁnding differences due to their lack of sensitivity. To
address this, scales should incorporate a broader range of
ratings. One global assessment scale that does include a
broad range is the percentage of normal function (Brin
et al. 1995). Perhaps the utility of this scale could be
improved by including descriptive anchors such as
50% = half of normal function, 90% = almost normal
function, etc. In this vein, it is interesting to note that some
of our patients have developed similar scales for them-
selves (e.g., diaries listing percentage of relief). The sen-
sitivity limitations with existing scales may be in part
overcome by the use of visual analogue scales or per-
centage function scales in which the patient may be asked,
for example, to rate the extent to which their disease limits
speciﬁc activities (e.g., reading, watching television,
working, participating in social activities). However, dia-
ries would be particularly important in these analyses
because it may be hard for patients to accurately remember
the extent of their limitations prior to treatment.
A related consideration is whether the scales are sensitive
enough for patients with mild disability or whether the scales
need to be adapted for this population, who mainly have dis-
comfort or psychosocial problems due to the visibility of the
blepharospasm but are not functionally restricted. For exam-
ple, in the study that used the BSDI as the primary outcome
measure, the mean scores on individual BSDI items before
injection were only 1.39 and 1.44 for the two groups, indi-
cating only mild impairment (Wabbels et al. 2010). In such
cases,theBSDIwouldnotdetectimprovementunlesssubjects
obtained a rating of 0, indicating no impairment. It may be
possible to address this issue by integrating several items that
pertain to the psychosocial or aesthetic aspects of blepharo-
spasm into existing scales.
Another related consideration is whether current scales
measure what is important to patients. The BSDI attempts
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is unclear whether these represent the aspects of blepha-
rospasm that are most important to patients. We have
observed that some patients return for their next BoNTA
injection when their scores on existing scales are ‘‘0’’
(zero). Although this could be a function of patients
seeking re-treatment before the effects of BoNT wear off, it
may represent the inadequacy of current scales in mea-
suring what is important to these patients. For instance,
more mildly affected patients often note that it is the
reaction of others to their eye spasms that is the most
bothersome aspect of their condition. This is not captured
on current scales, with the exception of the dystonia-spe-
ciﬁc quality of life scale, CDQ-24, which includes a stigma
subscale (Mu ¨ller et al. 2004). Of course, no scale can
capture every aspect of the condition that is important to all
patients. However, it may be possible to develop a scale
that permits patients to select the top 2 or 3 most bother-
some aspects of their condition and rate ‘‘percentage of
normal’’ on that variable following treatment. This would
represent an adaptation of the Disability Assessment Scale
that has been used to evaluate the effects of BoNTs in focal
spasticity (Brashear et al. 2002).
It may also be noted that there is more than one type of
blepharospasm. There is a ‘‘typical’’ blepharospasm, which
may be orbital, palpebral or mixed and may present as
either tonic or phasic. There is also a levator inhibition
subtype in which the major problem is opening the lid.
There may also be patients who present with a hybrid type
of blepharospsam that includes components of typical
blepharospasm and levator inhibition (Aramideh et al.
1994). True apraxia of the eyelid (not to be confused with
levator inhibition) is probably rare; by deﬁnition this is not
a dystonia and therefore it is not treated with BoNTA.
Existing scales do not address differences between sub-
types of blepharospasm.
Another consideration in the measurement of BoNT
effects is duration. Although duration has frequently been
used as a measure of BoNT efﬁcacy, it is imprecise and
deﬁnitions have varied or, in some cases, have not been
speciﬁed. For instance, total amelioration of symptoms for
4 weeks is not the same as a reduction in symptoms for
4 weeks (Nussgens and Roggenka ¨mper 1997). Another
challenge with measuring duration is that patients often
return for re-injection of BoNTA before the effects of their
previous treatment have completely worn off. For instance,
patients may know that symptoms recur after 13 weeks, so
they get injections every 12 weeks. Nevertheless, infor-
mation about BoNT action over time is important in
assessing the real effect of the medication over time and is
important to include in clinical studies.
Also critical in comparing different therapies for
blepharospasm, or any condition, is the clinical trial design.
The study must be adequately powered and the variability
controlled to permit detection of expected differences (i.e.,
avoidance of a type II or beta error). This may involve
ensuring that enough subjects are enrolled in the study and
designing the inclusion/exclusion criteria to reduce heter-
ogeneity in the study population. Crossover designs may be
useful, provided that adequate washout periods are allowed
between injections to preclude carryover effects. Admin-
istration of questionnaires prior to and following each
treatment may also be useful for minimizing differences
among subjects.
A ﬁnal important point has less to do with the assess-
ment scales than the doses of BoNTs. In studies that
compare different BoNTs, the products are typically
compared at set doses—usually corresponding to each
patient’s maintenance dose. Although physicians vary in
the doses administered, it is likely that these tend to be at or
near the top of the dose–response curve for each patient.
Thus, the products are compared at what may be the
asymptotic portions of the dose–response curves. If no
differences are found, some may interpret this as indicating
that the different BoNT products produce the same effects
at the same doses. However, this is not necessarily the
correct interpretation. A hypothetical example may be one
BoNT that produces a maximal effect at 1.25 U/site and
another that produces a maximal effect at 2.0 U/site. If the
products are compared at 2.5 U/site, the study may ﬁnd no
difference. However, if the BoNTs are compared across a
range of doses, differences may become evident and such
differences may be particularly evident at the lowest
effective doses.
Based on the aforementioned considerations, it seems
unlikely that any single measure is adequate to evaluate the
effects of treatment on blepharospasm. Objective measures
may not be sensitive to features of the condition that are
most important to patients, and subjective, patient-rated
scales may depend too much on the patient’s memory,
expectations, and psychological state at the time of rating.
In the absence of a mechanical or electronic device that
provides a valid measure of response to treatment, it seems
logical to rely on a combination of objective and subjective
rating scales. However, as described previously, current
measures lack sensitivity and thus we should seek to amend
these scales or develop new ones. In this pursuit, it will be
important to distinguish clinically meaningful differences
in improvement on the various measures, as (Jankovic
et al. 2009) have attempted to do for the JRS and BSDI.
However, smaller differences on more objective or sensi-
tive measures may also be important in the study of
BoNTs, as these could indicate pharmacological or potency
differences.
Our overall conclusion is that no single scale is broad
enough to capture the entire essential blepharospasm
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123experience; multiple scales are likely necessary to get a full
picture of this disorder. Additionally, existing scales are
not sensitive enough to differentiate the effects of different
BoNTs in clinical trials and may not be sensitive enough
for patients with mild blepharospasm. We recommend
(i) development of more sensitive scales, including the
pursuit of a valid biomechanical or electronic measurement
device and (ii) development of a scale that incorporates
symptoms that are known to be relevant to patients (e.g.,
selection of several symptoms for ratings).
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